IL1B and neoplasm: Interestingly, preclinical RCC data have demonstrated that inhibitors to CXCR2 [63], IL-1β [63], class I histone deacetylase (HDAC) [64], and HMGB1 [65] can slow tumor growth and potentially synergize with anti-PD-1 blockade in an MDSC inhibition-dependent manner.